e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients
F. Scano (Geneva, Switzerland)
Source:
Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Session:
Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Session type:
Symposium
Number:
123
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Scano (Geneva, Switzerland). The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients. Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy
Source: Eur Respir J 2004; 24: 11-17
Year: 2004
Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals?
Source: Eur Respir J 2005; 25: 751-757
Year: 2005
The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen
Source: Eur Respir J 2003; 21: 785-788
Year: 2003
Tuberculosis (TB) detection with HIV infected patients
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I
Year: 2012
Prevalence of HIV infection among tuberculosis cases and pattern of tuberculosis and treatment outcome in HIV seropositives – a study from a tuberculosis center from India
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Prevalence and treatment outcome of drug resistant pulmonary tuberculosis in HIV negative cases – experience from a tuberculosis treatment center in India
Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis
Year: 2009
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
The tuberculosis in patients with HIV and AIDS
Source: Eur Respir J 2007; 30: Suppl. 51, 656s
Year: 2007
Bronchoscopy yield in HIV positive patients, ten years on from the introduction of highly active anti-retroviral therapy
Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections
Year: 2009
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Impact of HIV status, CD4 count and antiretroviral treatment on tuberculosis treatment outcomes in a low-burden country
Source: International Congress 2017 – TB: co-morbidities and outcome
Year: 2017
Contribution of the T-SPOT.TB assay for differentiating active
versus
latent tuberculosis infection (LTBI)
Source: Annual Congress 2006 - New methods to diagnose tuberculosis infection
Year: 2006
Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection
Source: Eur Respir J 2010; 36: 1242-1247
Year: 2010
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis
Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease
Year: 2007
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
TB in children
Source: Eur Respir Mon 2012; 58: 206-218
Year: 2012
Characterization of the HBHA response in TB patients with or without HIV infection.
Source: International Congress 2017 – Human susceptibility to tuberculosis
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept